News & Updates

Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.

Compared with dapagliflozin, the glucagon-like peptide 1 liraglutide induces better lipid metabolism in patients with type 2 diabetes mellitus (T2DM), a recent study has found. However, this drug also comes with more adverse events than its sodium-glucose co-transporter 2 inhibitor comparator.

Taking vitamin D3 supplementation at 4,000 IU per day does not produce any safety concern and is well tolerated among overweight and obese participants who are at risk for diabetes, reports a study.